{"organizations": [], "uuid": "5784844d8ffbbe89832e897d9b6cf472c0e6fa69", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180328.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-neuland-laboratories-says-nclt-app/brief-neuland-laboratories-says-nclt-approved-scheme-of-amalgamation-between-co-neuland-health-sciences-neuland-pharma-research-idUSFWN1RA0EM", "country": "US", "domain_rank": 408, "title": "BRIEF-Neuland Laboratories Says ‍NCLT Approved Scheme Of Amalgamation Between Co, Neuland Health Sciences, Neuland Pharma Research", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.924, "site_type": "news", "published": "2018-03-28T19:20:00.000+03:00", "replies_count": 0, "uuid": "5784844d8ffbbe89832e897d9b6cf472c0e6fa69"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neuland-laboratories-says-nclt-app/brief-neuland-laboratories-says-nclt-approved-scheme-of-amalgamation-between-co-neuland-health-sciences-neuland-pharma-research-idUSFWN1RA0EM", "ord_in_thread": 0, "title": "BRIEF-Neuland Laboratories Says ‍NCLT Approved Scheme Of Amalgamation Between Co, Neuland Health Sciences, Neuland Pharma Research", "locations": [], "entities": {"persons": [], "locations": [{"name": "hyderabad", "sentiment": "none"}], "organizations": [{"name": "neuland pharma research", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "neuland laboratories ltd", "sentiment": "negative"}, {"name": "nclt approved scheme of amalgamation between co", "sentiment": "negative"}, {"name": "neuland health sciences", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28 (Reuters) - Neuland Laboratories Ltd:\n* NCLT, HYDERABAD BENCH, APPROVED SCHEME OF AMALGAMATION BETWEEN CO, NEULAND HEALTH SCIENCES, NEULAND PHARMA RESEARCH Source text - bit.ly/2pMc2jy Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://bit.ly/2pMc2jy", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-28T19:20:00.000+03:00", "crawled": "2018-03-29T15:25:49.003+03:00", "highlightTitle": ""}